Geron (GERN) Non-Current Assets (2010 - 2026)
Geron's (GERN) quarterly Non-Current Assets came in at $32.7 million in Q2 2026, down 34.14% year-over-year from $49.6 million in Q2 2025, and down 8.2% quarter-over-quarter from $35.6 million in Q1 2026.
Analysis
Geron (GERN) Non-Current Assets (2010 - 2026) Analysis & Trends
Geron has disclosed Non-Current Assets across 17 years of filings, most recently posting $32.7 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 34.14% year-over-year to $32.7 million; the TTM figure through Jun 2026 stood at $163.6 million (down 38.5% YoY), while the FY2025 annual figure was $50.3 million, down 51.09% from the prior year.
- Non-Current Assets came in at $32.7 million for Q2 2026 at Geron, down from $35.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $102.8 million in Q4 2024 to a low of $10.3 million in Q4 2022.
- Average Non-Current Assets over 5 years is $44.3 million, with a median of $41.5 million recorded in 2023.
- Year-over-year, Non-Current Assets slumped 78.82% in 2022 and jumped 639.67% in 2023.
- Over 5 years, Non-Current Assets stood at $10.3 million in 2022, then surged by 410.49% to $52.7 million in 2023, then surged by 94.94% to $102.8 million in 2024, then plunged by 51.09% to $50.3 million in 2025, then sank by 35.01% to $32.7 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $32.7 million in Q2 2026, $35.6 million in Q1 2026, and $50.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 32.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.67 Mn |
| Mar 31, 2026 | 35.59 Mn |
| Dec 31, 2025 | 50.27 Mn |
| Sep 30, 2025 | 45.04 Mn |
| Jun 30, 2025 | 49.60 Mn |
| Mar 31, 2025 | 66.68 Mn |
| Dec 31, 2024 | 102.79 Mn |
| Sep 30, 2024 | 46.89 Mn |
| Jun 30, 2024 | 76.09 Mn |
| Mar 31, 2024 | 30.57 Mn |
| Dec 31, 2023 | 52.73 Mn |
| Sep 30, 2023 | 77.93 Mn |
| Jun 30, 2023 | 38.02 Mn |
| Mar 31, 2023 | 37.85 Mn |
| Dec 31, 2022 | 10.33 Mn |
| Sep 30, 2022 | 10.54 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 22.50 Mn |
| Dec 31, 2021 | 38.83 Mn |
| Sep 30, 2021 | 49.74 Mn |